Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Liabilities (2016 - 2025)

Sangamo Therapeutics has reported Total Liabilities over the past 16 years, most recently at $74.0 million for Q4 2025.

  • Quarterly results put Total Liabilities at $74.0 million for Q4 2025, down 6.15% from a year ago — trailing twelve months through Dec 2025 was $74.0 million (down 6.15% YoY), and the annual figure for FY2025 was $74.0 million, down 6.15%.
  • Total Liabilities for Q4 2025 was $74.0 million at Sangamo Therapeutics, down from $82.4 million in the prior quarter.
  • Over the last five years, Total Liabilities for SGMO hit a ceiling of $407.7 million in Q1 2021 and a floor of $69.3 million in Q2 2024.
  • Median Total Liabilities over the past 5 years was $88.1 million (2023), compared with a mean of $182.7 million.
  • Biggest five-year swings in Total Liabilities: surged 114.72% in 2021 and later crashed 70.23% in 2023.
  • Sangamo Therapeutics' Total Liabilities stood at $346.6 million in 2021, then dropped by 22.8% to $267.6 million in 2022, then tumbled by 69.19% to $82.4 million in 2023, then fell by 4.33% to $78.9 million in 2024, then dropped by 6.15% to $74.0 million in 2025.
  • The last three reported values for Total Liabilities were $74.0 million (Q4 2025), $82.4 million (Q3 2025), and $78.0 million (Q2 2025) per Business Quant data.